Evidence map›Paper›PMID 30479323›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2018

Appraisal of Basic-Hemostatic Markers in Lung Cancer Patients During Follow-Up Care After Radiotherapy Treatment.

Edyta I Wolny-Rokicka, Jerzy Wydmański, Andrzej Tukiendorf, Piotr Mróz, Agnieszka Zembroń-Łacny

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Determination of Risk Factors Related to Supraclavicular Recurrence for Limited-Stage Small Cell Lung Cancer (SCLC) Patients.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Article
  5. The Correlation of Blood Parameters with Size in Cases of Neoplastic TumorAsian Pacific journal of cancer prevention : APJCP · 2019
    Article
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Edyta I Wolny-RokickaDepartment of Radiotherapy, Provincial Multidisciplinary Hospital, Gorzów Wielkopolski, Poland.
Jerzy WydmańskiDepartment of Radiotherapy, Center of Oncology - Maria Skłodowska-Curie Memorial Institute, Branch in Gliwice, Gliwice, Poland.
Andrzej TukiendorfDepartment of Social Medicine, Medical University in Wrocław, Wrocław, Poland.
Piotr MrózFaculty of Computer Science, Electrical Engineering and Automation, Institute of Metrology, Electronics and Computer Science, University of Zielona Góra, Zielona Góra, Poland.
Agnieszka Zembroń-ŁacnyFaculty of Medicine and Health Sciences, University of Zielona Góra, Zielona Góra, Poland.
University of Zielona Góra · PLThe Maria Sklodowska-Curie National Research Institute of Oncology · PLWroclaw Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND The aim of this paper was to investigate the association between clinicopathological factors and the coagulation test in lung cancer patients during follow-up care after treatment. MATERIAL AND METHODS Ninety-five medical patients with histologically proven advanced lung carcinoma (LC) who had undergone radiotherapy were prospectively reviewed between January 2014 and December 2016. The study investigated the relationship between the biochemical results, the disease stage, and the survival rate in lung cancer patients. Post-treatment coagulation-based D-dimer (DD), fibrinogen (Fib), and complete blood count (CBC) were evaluated during the follow-up over a period of 2 years after treatment or until the patient's death. RESULTS An increase of D-dimer generates an increased chance of early death by approximately 0.03% per 1 D-dimer unit. In cases when the difference in the D-dimer concentration equals 1000, the risk of an early death increases by (1.00031000-1)×100%=35%. CONCLUSIONS High levels of D-dimer are associated with an advanced form of disease with metastasis and higher risk of early death in lung cancer patients.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorBlood Cell CountBlood CoagulationCarcinoma, Non-Small-Cell LungFemaleHemostasisHemostaticsHemostatic TechniquesHumansLung NeoplasmsMaleMiddle AgedPrognosisBiomarkers, TumorHemostatics

Identifiers

PMID30479323
PMCPMC6278351
OpenAlexW2902738569

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.